TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mesoblast Limited ( (AU:MSB) ) has provided an announcement.
Mesoblast Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability in management and oversight. This release is significant as it reinforces Mesoblast’s dedication to maintaining high governance standards, potentially impacting investor confidence and stakeholder trust.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a company operating in the biotechnology industry, focusing on developing innovative cellular medicines. The company is involved in creating treatments for inflammatory diseases, cardiovascular diseases, and back pain, among other conditions.
YTD Price Performance: -17.10%
Average Trading Volume: 4,970,723
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.3B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.